A Phase 3 interventional study of Rituximab and Obinutuzumab in Diffuse Large B-Cell Lymphoma, sponsored by Hoffmann-La Roche. Terminated at 235 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-12.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse — 4 open to participants now, 6 under way, none of them phase 3. obinutuzumab · Lymphoma, Large B-Cell, Diffuse.
Among the 17 studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse, this one has the largest enrollment, is the only one that started in 2011, is the only one in phase 3, and was the 1st registered.
1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.
Browse Lymphoma, Large B-Cell, Diffuse studies →4 of the 17 studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18+
Liling Zhang · Sites in China
Ages 18–75
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
New York Medical College · Sites in United States
Ages 3–31
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 13 · Phase 3 1
First in 2011; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,418 is above the median of 44 across 1,501 interventional studies indexed under Lymphoma, Large B-Cell, Diffuse.
Median enrollment 48 across the 17 interventional studies. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 17 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
28 studies in Lymphoma, Large B-Cell, Diffuse by Hoffmann-La Roche: 2 open now, 5 under way, 1 of them phase 3. Of 22 finished, 13 (59%) have results posted.
Among the 28 studies in Lymphoma, Large B-Cell, Diffuse by Hoffmann-La Roche, this one has the largest enrollment of the 22 interventional ones that give a count, is one of 3 that started in 2011, is one of 7 in phase 3, and was the 2nd registered.
Hoffmann-La Roche’s Lymphoma, Large B-Cell, Diffuse studies by the year they started, since 2005.
2 of the studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 17 studies testing obinutuzumab in Lymphoma, Large B-Cell, Diffuse, from their registry updates:
Among Hoffmann-La Roche’s 28 in Lymphoma, Large B-Cell, Diffuse:
This tab as a report to print or save as PDF → With an account.
This open-label, randomized, parallel group study will evaluate the efficacy and safety of obinutuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisolone or prednisone (CHOP) chemotherapy versus rituximab (MabThera/Rituxan) with CHOP in previously untreated participants with cluster of differentiation 20 (CD20)-positive diffuse large B-cell lymphoma (DLBCL). Participants will be randomized to receive either obinutuzumab 1000 milligrams (mg) intravenously (IV) every 21 days or rituximab 375 milligrams per square meter (mg/m\^2) IV every 21 days for 8 cycles, in addition to 6-8 cycles of CHOP chemotherapy IV every 21 days. Participants randomized to the obinutuzumab arm will receive an additional two doses on Days 8 and 15 of Cycle 1. Anticipated time on study treatment is 24 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
Drug: Rituximab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Participants received eight 21-day cycles of obinutuzumab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
Drug: Obinutuzumab · Drug: Cyclophosphamide · Drug: Doxorubicin · Drug: Vincristine · Drug: Prednisone
Rituximab at a dose of 375 mg/m\^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
Also known as: MabThera, Rituxan
Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
Also known as: GA101, RO5072759
Cyclophosphamide 750 milligrams per square metre (mg/m\^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
Doxorubicin 50 mg/m\^2 IV, administered on Day 1 of each 21-day cycle.
Vincristine 1.4 mg/m\^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
Median Time to Progression-Free Survival (PFS), Investigator-Assessed
Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease \[PD\]). Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed
Kaplan Meier estimate of median PFS was defined as time at which half of participants have progressed (progressive disease \[PD\]). Progression-free survival was defined as time from randomization until first documented day of disease progression or relapse, using a modified version of Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 cm or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT or MRI. This outcome measure used data from primary analysis which included all 1418 participants.
Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Median Time to Overall Survival (OS)
Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death. Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause.
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Overall Response Rate (ORR), Investigator-Assessed
Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Overall Response Rate (ORR), IRC-Assessed
Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. This outcome measure used data from primary analysis which included all 1418 participants.
Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Complete Response (CR) at the End of Treatment, Investigator-Assessed
Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Complete Response (CR) at the End of Treatment, IRC-Assessed
Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. This outcome measure used data from primary analysis which included all 1418 participants.
Time frame: Baseline up to approximately 4 years and 9 months (up to 29 April 2016)
Median Time to Event-Free Survival (EFS), Investigator-Assessed
Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed. Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non-protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.
Time frame: Baseline up to death or disease progression, or initiation of new anti-lymphoma treatment (NALT), whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Median Time to Disease-Free Survival (DFS), Investigator-Assessed
Kaplan Meier estimate of median DFS was defined as time at which half of participants have disease progression/relapse or death from any cause. Disease-free survival was defined as time from date of the first occurrence of a documented CR to date of disease progression/relapse or death from any cause on basis of investigator assessments with use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.
Time frame: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Duration of Response (DOR), Investigator-Assessed
DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression \>/= 50%. Progression/relapse: at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 cm or \>/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%.
Time frame: Baseline up to death or disease progression, whichever occurred first, approximately 6.5 years (up to 31 January 2018)
Time to Next Anti-Lymphoma Treatment (TTNALT)
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause.
Time frame: Baseline up to start of next anti-lymphoma treatment or death due to any cause, whichever occurred first, approximately 6.5 years (31 January 2018)
Percentage of Participants With Adverse Events (AEs)
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Time frame: Baseline up to approximately 6.5 years (up to 31 January 2018)
Percentage of Participants With Human Anti-Human Antibodies (HAHAs) to Obinutuzumab
The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants.
Time frame: Pre-dose (Hour 0) on Cycle (C) 4 Day (D) 1, at end of treatment/early termination (up to Month 6), every 6 months thereafter for 30 months (cycle length = 21 days)
Change From Baseline in Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym) Subscale Score
The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement.
Time frame: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to approximately 6.5 years, (cycle length = 21 days)
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) Domain Scores
The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants.
Time frame: Baseline (pre-dose [Hour 0] on C1D1), C3D1, end of treatment (up to Month 6), every 12 months thereafter up to data cut-off, up to approximately 6.5 years, (cycle length = 21 days)
Serum Concentrations of Obinutuzumab in Japanese Participants With Diffuse Large B-Cell Lymphoma (DLBCL)
Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab.
Time frame: C1: D1 post-infusion and 20-28 and 66-80 hours after end of infusion, D8 and D15 pre-and post-infusion; C2: D1 pre- and post-infusion; C4: D1 pre- and post-infusion; C6: D1 pre- and post-infusion; C8: D1 pre- and post-infusion (cycle length = 21 days)
| Milestone | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Started | 712 | 706 |
| Completed | 86 | 91 |
| Not completed | 626 | 615 |
| Withdrew: Withdrawal by subject | 35 | 38 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Physician decision | 15 | 23 |
| Withdrew: Non-compliance | 8 | 6 |
| Withdrew: Lost to follow-up | 10 | 8 |
| Withdrew: Death | 32 | 44 |
| Withdrew: Adverse event | 4 | 6 |
| Withdrew: Study terminated by sponsor | 307 | 315 |
| Withdrew: Progressive disease | 190 | 166 |
| Withdrew: Reason not specified | 23 | 9 |
Kaplan Meier estimate of the median PFS was defined as the time at which half of the participants have progressed (progressive disease \[PD\]). Progression-free survival was defined as the time from randomization until the first documented day of disease progression or relapse, using a modified version of the Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by computed tomography (CT) or magnetic resonance imaging (MRI).
| months | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Median Time to Progression-Free Survival (PFS), Investigator-Assessed | 74.5 (NA to NA) | 68.3 (68.3 to NA) |
Kaplan Meier estimate of median PFS was defined as time at which half of participants have progressed (progressive disease \[PD\]). Progression-free survival was defined as time from randomization until first documented day of disease progression or relapse, using a modified version of Revised Response Criteria for Malignant Lymphoma, or death from any cause, whichever occurred first, on basis of IRC assessments. Progression was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 cm or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT or MRI. This outcome measure used data from primary analysis which included all 1418 participants.
| months | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Median Time to Progression-Free Survival (PFS), Independent Review Committee (IRC)-Assessed | NA (NA to NA) | NA (NA to NA) |
Kaplan Meier estimate of median OS was defined as the time at which half of the participants had died, regardless of the cause of death. Overall survival in the overall study population was defined as the time from the date of randomization to the date of death from any cause.
| months | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Median Time to Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
Overall response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites.
| percentage of participants | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 80.1 | 81.4 |
| With PET | 77.6 | 77.1 |
Overall response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Overall response was defined as the disappearance of all evidence of disease, regression of measurable disease, and no new sites. This outcome measure used data from primary analysis which included all 1418 participants.
| percentage of participants | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 80.2 | 82.3 |
| With PET | 81.1 | 82.1 |
Percentage of participants with complete response was determined on the basis of investigator assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease.
| percentage of participants | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 33.9 | 35.4 |
| With PET | 59.1 | 56.5 |
Percentage of participants with complete response was determined on the basis of IRC assessments according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma, 2007. Tumor assessments were performed with CT/MRI with or without PET. Complete response was defined as the disappearance of all evidence of disease. This outcome measure used data from primary analysis which included all 1418 participants.
| percentage of participants | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Without PET | 34.4 | 39.1 |
| With PET | 65.3 | 66.7 |
Kaplan Meier estimate of median EFS is the time at which half of the participants have progressed. Event-free survival was defined as the time from the date of randomization until the date of disease progression, relapse, initiation of a new non-protocol-specified anti-lymphoma treatment, or death from any cause on the basis of investigator assessments with the use of Revised Response Criteria for Malignant Lymphoma. Disease progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. Tumor measurements were obtained by CT/MRI.
| months | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Median Time to Event-Free Survival (EFS), Investigator-Assessed | 74.5 (NA to NA) | 68.3 (68.3 to NA) |
Kaplan Meier estimate of median DFS was defined as time at which half of participants have disease progression/relapse or death from any cause. Disease-free survival was defined as time from date of the first occurrence of a documented CR to date of disease progression/relapse or death from any cause on basis of investigator assessments with use of Revised Response Criteria for Malignant Lymphoma. Tumor assessments were performed with CT/MRI. CR was defined as disappearance of all target lesions. Progression/relapse was defined as at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 centimeter (cm) or \>/= 50% increase in other target measurable lesions (e.g., splenic or hepatic nodules) and/or appearance of any new bone marrow involvement and/or appearance of any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm.
| months | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Median Time to Disease-Free Survival (DFS), Investigator-Assessed | NA (NA to NA) | 65.4 (NA to NA) |
DOR: time from first occurrence of documented CR or PR to disease progression/relapse, or death from any cause for participants with a response of CR or PR. Tumor assessments were performed with CT/MRI. CR: disappearance of all target lesions. PR: \>/=50% decrease target lesions in up to six dominant lesions identified at baseline, no new lesions and no increase in the size of the liver, spleen, or other nodes. Splenic and hepatic nodule regression \>/= 50%. Progression/relapse: at least 50% increase in nodal lesions or \>/=50% increase in any node \> 1 cm or \>/= 50% increase in other target lesions (e.g., splenic or hepatic nodules) and/or any new bone marrow involvement and/or any new lesion \> 1.5 cm or \>/= 50% increase in any previously involved node with a diameter \</= 1 cm such that it is now \>1.5 cm. A participant in the Rituximab+CHOP arm with the longest follow-up, 53 months, had an event. The criterion for median was the minimum time when survival went below 50%.
| months | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Duration of Response (DOR), Investigator-Assessed | 71.9 (NA to NA) | NA (65.4 to NA) |
Time to next anti-lymphoma treatment was defined as the time from the date of randomization to the start date of the next anti-lymphoma treatment or death from any cause.
| months | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Time to Next Anti-Lymphoma Treatment (TTNALT) | NA (74.5 to NA) | NA (NA to NA) |
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
| percentage of participants | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) | 95.3 | 98.1 |
The presence of HAHAs to obinutuzumab was assessed in the first 100 randomized participants.
| percentage of participants | Obinutuzumab+Chemotherapy |
|---|---|
| Screening | 2.0 |
| Cycle 4 Day 1 | 0 |
| Study Completion / Early Discontinuation | 0 |
| Follow-Up Month 6 | 0 |
| Follow-Up Month 12 | 0 |
| Follow-Up Month 18 | 0 |
| Follow-Up Month 24 | 0 |
| Follow-Up Month 30 | 0 |
| Follow-Up Completion/ Early Discontinuation | 0 |
| Unscheduled | 0 |
The FACT-Lym subscale was developed to assess health-related quality of life in participants with non-Hodgkin lymphoma. The score range is 0-60, with higher scores indicating better outcomes. A positive change from baseline indicates an improvement.
| score on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Baseline | 45.34 ± 10.16 | 45.18 ± 9.86 |
| Score Change, Cycle 3 Day 1 | 3.83 ± 8.65 | 3.70 ± 9.13 |
| Score Change, Study Compl./Discont. | 5.03 ± 10.21 | 4.35 ± 11.03 |
| Score Change, Follow-Up Month 12 | 6.37 ± 10.12 | 6.18 ± 10.51 |
| Score Change, Follow-Up Month 24 | 7.07 ± 10.35 | 6.66 ± 10.50 |
| Score Change, Follow-Up Month 30 | — | 25.00 ± NA |
| Score Change, Follow-Up Month 36 | 7.57 ± 10.16 | 7.31 ± 10.67 |
| Score Change, Follow-Up Month 48 | 8.22 ± 9.65 | 7.37 ± 10.45 |
| Score Change, Follow-Up Term./Compl. | 5.51 ± 10.04 | 5.55 ± 10.62 |
The EORTC QLQ-C30 is a health-related quality of life questionnaire. A higher score indicates better quality of life, with changes of 5 to 10 points considered to be a minimally important difference to participants.
| score on a scale | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Baseline | 59.81 ± 24.39 | 58.55 ± 25.23 |
| Change Baseline, Cycle 3 Day 1 | 6.37 ± 23.77 | 7.51 ± 25.99 |
| Change Baseline, Study Completion | 9.84 ± 25.96 | 10.22 ± 30.17 |
| Change Baseline, Follow-Up Month 12 | 12.67 ± 26.31 | 13.84 ± 29.97 |
| Change Baseline, Follow-Up Month 24 | 14.74 ± 26.33 | 15.81 ± 29.24 |
| Change Baseline, Follow-Up Month 30 | — | 58.33 ± NA |
| Change Baseline, Follow-Up Month 36 | 15.01 ± 26.85 | 17.99 ± 28.85 |
| Change Baseline, Follow-Up Month 48 | 16.62 ± 27.49 | 17.53 ± 30.31 |
| Change Baseline, Follow-Up Completion | 8.74 ± 29.40 | 8.46 ± 28.71 |
Serum samples for assessment of obinutuzumab serum concentrations were collected only from a subset of Japanese participants following administration of 1000 mg obinutuzumab.
| micrograms per milliliter (μg/mL) | Obinutuzumab+Chemotherapy |
|---|---|
| Cycle 1, Day 8 pre-infusion | 174 ± 38.7 |
| Cycle 1, Day 15 pre-infusion | 320 ± 39.2 |
| Cycle 2, Day 1 pre-infusion | 431 ± 39.8 |
| Cycle 4, Day 1 pre-infusion | 352 ± 42.1 |
| Cycle 6, Day 1 pre-infusion | 378 ± 45.9 |
| Cycle 8, Day 1 pre-infusion | 478 ± 43.9 |
| Cycle 1, Day 1 post-infusion | 435 ± 32.3 |
| Cycle 1, Day 1 20-28 hours after end of infusion | 259 ± 56.3 |
| Cycle 1, Day 1 66-80 hours after end of infusion | 219 ± 51.2 |
| Cycle 1, Day 8 post-infusion | 578 ± 37.8 |
| Cycle 1, Day 15 post-infusion | 718 ± 32.9 |
| Cycle 2, Day 1 post-infusion | 938 ± 31.3 |
| Cycle 4, Day 1 post-infusion | 817 ± 28.6 |
| Cycle 6, Day 1 post-infusion | 813 ± 32.6 |
| Cycle 8, Day 1 post-infusion | 881 ± 35.9 |
Collected over 6 years and 7 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab+Chemotherapy | — | 269/701 (38.4%) | 613/701 (87.4%) |
| Obinutuzumab+Chemotherapy | — | 312/702 (44.4%) | 646/702 (92%) |
| Event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 71/701 | 85/702 |
| NeutropeniaBlood and lymphatic system disorders | 38/701 | 54/702 |
| PneumoniaInfections and infestations | 33/701 | 43/702 |
| PyrexiaGeneral disorders | 11/701 | 17/702 |
| SepsisInfections and infestations | 10/701 | 16/702 |
| LeukopeniaBlood and lymphatic system disorders | 6/701 | 14/702 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/701 | 12/702 |
| Septic shockInfections and infestations | 3/701 | 12/702 |
| AnaemiaBlood and lymphatic system disorders | 6/701 | 9/702 |
| Atrial fibrillationCardiac disorders | 4/701 | 9/702 |
| Event | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 269/701 | 315/702 |
| Infusion related reactionInjury, poisoning and procedural complications | 162/701 | 251/702 |
| NauseaGastrointestinal disorders | 199/701 | 210/702 |
| ConstipationGastrointestinal disorders | 177/701 | 167/702 |
| AlopeciaSkin and subcutaneous tissue disorders | 144/701 | 148/702 |
| PyrexiaGeneral disorders | 75/701 | 137/702 |
| FatigueGeneral disorders | 124/701 | 136/702 |
| ChillsGeneral disorders | 37/701 | 132/702 |
| LeukopeniaBlood and lymphatic system disorders | 90/701 | 117/702 |
| DiarrhoeaGastrointestinal disorders | 91/701 | 113/702 |
The intent-to-treat (ITT) population included all randomized participants. However, 4 patients were classified as misconduct patients and were not included in the ITT population.
| Age, Continuous(years) | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy | Total |
|---|---|---|---|
| Mean | 59.1 ± 13.6 | 59.4 ± 13.3 | 59.2 ± 13.5 |
| Sex: Female, Male(Participants) | Rituximab+Chemotherapy | Obinutuzumab+Chemotherapy | Total |
|---|---|---|---|
| Female | 328 | 336 | 664 |
| Male | 382 | 368 | 750 |
Showing the first 100 of 235 sites across 29 countries. Choose a country and city above to see the rest.
Ran from Jul 2011 to primary completion in Apr 2016, 57 months.
Results were first posted in Aug 2017, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab
Lymphoma, Large B-Cell, Diffuse →